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Abstract
Background: We present a rare early presentation of a ADCK4-related glomerulopathy. This case is of interest as
potentially treatable if genetic results are timely obtained.
Case presentation: We report the case of a 5-year-old boy who was identified with significant proteinuria by a urinary
routine screening program for school children. Physical examination revealed dysplastic ears and abnormal folded pinna.
Albumin level was 41 g/L (39–53 g/L), and urine proteins/creatinine ratio was 2.6 g/g. Renal ultrasound showed enlarged
kidneys and perimedullary hyperechogenicity. Treatment by angiotensin-converting-enzyme inhibitor was not beneficial.
Renal biopsy showed signs of focal segmental glomerulosclerosis. After 4 years of follow-up, he developed a clinical
nephrotic syndrome and no response to prednisone and other immunosuppressive agents was obtained. Within 6 months,
he was in end-stage-renal-failure (ESRF) and hemodialysis was started. He was transplanted at 10 years with
his mother’s kidney. Genes known to be responsible in steroid-resistant nephrotic syndromes were tested. Our
patient is compound heterozygous for two mutations in the aarF domain-containing-kinase 4 (ADCK4) gene. ADCK4 gene
is one of the genes involved in coenzyme Q10 (CoQ10) biosynthesis, is located in chromosome 19q13.2 and expressed in
podocytes. ADCK4 mutations show a largely renal-limited phenotype. The nephropathy usually presents during
adolescence, fast evolves towards ESRF, and may be treatable by CoQ10 supplementation if started early in the disease.
Our patient presented nephrotic range proteinuria at 5 years, and he reached ESRF at 10 years.
Conclusion: ADCK4-related glomerulopathy is an important novel and potentially treatable cause of isolated
nephropathy not only in adolescents, but also in children in their first decade of life. Discovery of important proteinuria in
an asymptomatic child should prompt early genetic investigations.
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Background
Five to 10% of children and adolescents screened at
school for proteinuria present a positive urine dipstick
(defined as ≥1+). However, only 0.1% of them have
persistent proteinuria [1]. This small subset of children
might hide a serious renal disease. Isolated persistent
proteinuria of nephrotic range (defined as >50 mg/kg/day
or urinary proteins/creatinine ratio ≥ 2 g/g) in an otherwise
asymptomatic child, is initially investigated by biochemical,
viral and immunological analyses. Renal biopsy is also
eventually performed. Mutations of genes involved in the
podocyte function are traditionally explored mainly in case
of steroid-resistant nephrotic syndrome (SRNS), suspicion
of syndromic disease or evolution towards renal failure. In
the last 20 years, genetics has made tremendous advances
in this field. Currently, at least 27 genes are known to cause
SRNS [2]. These genetic mutations affect proteins that are
expressed in a variety of locations within the podocyte (e.g.
the cell membrane, nucleus, cytoskeleton, lysosomes and
mitochondria). Altogether, a single-gene cause is found in
nearly 30% of cases of SRNS, and probability to identify a
single-gene cause is inversely correlated with the age of
disease onset [2]. Until few years ago, each gene was inves-
tigated separately, and the choice of genes to be firstly
screened for mutations depended on the patient’s age,
disease presentation and result of renal biopsy [3]. More-
over, patients who did not present in the typical way, risked
to be misdiagnosed and unnecessarily treated with toxic
immunosuppressive drugs. The evolution of genetics tools
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and the current use of high-throughput analysis allow
nowadays the simultaneous screening of all the known
genes implicated in the podocyte development, structure
and function and eventually in the development of
nephrotic syndrome. The consequences are quicker diagno-
ses, possibly allowing the avoidance of ineffective treat-
ments and the promptly start of potentially beneficial
drugs. Indeed, it seems that about 1% of patients affected
with a SRNS carry mutations in genes that function within
the coenzyme Q10 (CoQ10) biosynthesis pathway, suggest-
ing that SRNS may be treatable in these individuals with
CoQ10 supplementations [2, 4]. Here, we report the case of
a patient who showed an unusual clinical presentation of
heavy proteinuria and had been only recently diagnosed
with the help of the new genetic techniques.
Case presentation
A 5-year-old boy was identified with proteinuria by a
urinary screening program for school children. At that
time his medical history was marked by recurrent otitis
and tonsillitis, and an episode of bronchopneumonia.
Parents were healthy, non-consanguineous and of
Caucasian origin. His older brother presented an hypo-
plasia of the left ear pinna, an atresia of the left external
ear canal with a hearing loss. The brother presented no
proteinuria, and all the renal investigations resulted as
normal. Physical examination of our patient revealed no
edema, normal male external genitalia, dysplastic ears
with abnormal folded pinna, a short uvula, normal
filtrum, a thin superior lip, with normal body weight and
height for chronological age. A moderate hearing loss
was initially present, but it disappeared after myringot-
omy, and insertion of ventilation tube was performed.
Blood pressure was normal, no hematuria was ob-
served. Laboratory investigations revealed no hypoalbu-
minemia (41 g/L), and urine contained nephrotic-range
glomerular proteins (proteins/creatinine: 2.6 g/g). All the
other biochemical investigations (viral serology and
immunological analyses) were normal, and glomerular
filtration rate (GFR) measured by creatinine clearance
was within the normal range (100 ml/min/1.73 m2).
Renal ultrasound showed enlarged kidneys and perime-
dullary hyperechogenicity. A treatment by an angiotensin-
converting-enzyme inhibitor was started with no
improvement of the proteinuria.
Confronted with this clinical picture of external ear
malformations and renal anomalies complicated by
heavy proteinuria, a first genetic test was performed few
weeks after his first nephrology consultation in order to
exclude a branchio-oto-renal (BOR) syndrome. The
NPHS2 podocine gene was also tested, but these first
genetic investigations were negative. Renal biopsy
showed focal segmental glomerulosclerosis (FSGS) with
signs of severe sclerosis in 65% of glomeruli. At age of
8 years, proteinuria increased (proteins/creatinine ratio:
5.4 g/g), renal function deteriorated (plasma creatinine:
0.8 mg/dL), but plasma albumin remained within normal
values. At the age of 9 years, he developed a nephrotic
syndrome (plasma albumin: 29 g/L) responding neither
to a 4 weeks steroid treatment, nor to other immuno-
suppressive agents (cyclosporine A and mycophenolate
mofetil) introduced successively. At the age of 10 years,
the child was admitted in the intensive care unit for a
1st and unique non-febrile episode of seizure, in a
context of high steroid dosage and hypertension. Five
years after his first presentation, he evolved towards an
ESRF, and hemodialysis was started. He was eventually
transplanted without incidents few months later with his
mother’s kidney.
All suspected genes implicated in SRNS have been inves-
tigated (NPHS1, CD2AP, PLCE1, ACTN4, TRPC6, INF2,
and COQ genes) using a combination of custom designed
multi-gene NGS panel for FSGS and related glomerulopa-
thies [5]. High-throughput sequencing was performed on
the MiSeq/HiSeq platform (Illumina, San Diego, CA). All
findings were confirmed by Sanger sequencing, which was
also used to family carrier screening.
Mutational analysis revealed a previously reported mis-
sense mutation (c.748G >T, residue change p. Asp250Tyr)
[5] and a novel sequence variant (c.649G >A, residue
change p.Ala217Thr) within the aarF domain containing
kinase 4 (ADCK4) gene inherited from both parents (Fig. 1).
The c.649G >A change corresponds to a very rare single-
nucleotide variant reported in the Exome Aggregation
Consortium (ExAC) database with an allele frequency of
0.00015 (18 alleles count/1190492 alleles), mainly observed
in the European non-Finnish population (12/18 alleles). It
involves a highly conserved residue within the kinase
(ABC1 subdomain) and all mutation software’s prediction
concluded to a pathogenic effect (https://varsome.-
com/variant/hg19/adck4%3Ac.649G%3EA, Fig. 2).
Discussion
Asymptomatic children presenting with heavy proteinuria
may eventually develop nephrotic syndrome. Approxi-
mately 10% of nephrotic syndrome cases are steroid-
resistant, and these patients are at particular risk of
developing ESRF. They should be promptly investigated,
and genetic causes excluded.
The pathophysiology of SRNS varies, presenting as
isolated or as part of a syndrome. As regards to the non-
syndromic forms, some are related to a still not
completely understood underlying immune disorder,
while an increasing number is found to be caused by
mutations in genes highly expressed in podocytes (e.g.
NPHS1, NPHS2, CD2AP, PLCE1, ACTN4, TRPC6, and
INF2). Syndromic forms of SRNS, may be due to muta-
tions in genes coding transcriptional factors (e.g. WT1),
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glomerular basement membrane components (e.g.
LAMB2), or mitochondrial proteins as the CoQ10 (e.g.
COQ genes) [6].
CoQ10 is a lipid involved in many cellular processes,
such as energy production through the mitochondrial
respiratory chain, pyrimidine biosynthesis and beta-
oxidation of fatty acids. It is an important anti-oxidant,
and is also involved in the apoptosis process.
CoQ10 deficiency is implicated in several disorders, such
as neurodegenerative diseases, cancer, cardiovascular
diseases, diabetes mellitus, and aging. Rarer conditions exist
which are caused by a primary or secondary deficiency of
CoQ10 in tissues [7, 8].
In humans, to date 18 genes are known to be involved
in CoQ10 biosynthesis. Mutations in eight of these genes
(PDSS1, PDSS2, COQ2, COQ4, COQ6, ADCK3, ADCK4,
and COQ9) have been associated with the rare primary
forms of CoQ10 deficiency. They are usually transmitted
as autosomal recessive traits, and are very heterogeneous
clinically and genetically.
These genes have a pleiotropic action, as mutations in
the same gene are related to several clinical features. Most
clinical phenotypes include numerous combinations of
encephalomyopathy, deafness, visual impairment, cerebellar
ataxia, seizures and cardiomyopathy. At least four genes
include SRNS (COQ2, COQ6, PDSS2, ADCK4) [9]. The
clinical variability of CoQ10 deficiency concerns not only
the pattern of tissue involvement, but also the severity of
the disease, the age of onset (from birth to adulthood), and
the clinical response to CoQ10 supplementation [7].
In our patient we identified one previously reported
missense mutation and a novel sequence variant in the
ADCK4 gene with a pathogenic effect. ADCK4 is one of
the genes involved in CoQ10 biosynthesis. It is located
in chromosome 19q13.2, expressed in podocytes and
localizes to mitochondria and foot processes [9]. Defects
in ADCK4 are increasingly discovered and up to now 15
different mutations (both frameshift and missense) have
been reported in 30 patients affected with SRNS from 17
families without established genotype-phenotype correla-
tions [5, 9]. All these patients presented SRNS and
FSGS, predominantly with a largely renal-limited pheno-
type, and some neurologic dysfunction in 20% of the
cases. The disease is mainly discovered in adolescence
with a mild-moderate proteinuria with no or mild
edema, and a rapid progression towards ESRF (median
Fig. 1 ADCK4 sequence chromatogram showing the two heterozygous mutations found in index patient
Fig. 2 Results of bioinformatics tools applied to predict mutational effects on ADCK4
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of 9 months from the diagnosis) [5]. The median age for
the need of renal replacement therapy is 16 years [5],
which is quite late comparing to patients with other
genetic-related nephrotic syndromes. In line with the
ADCK4 cases reported, our patient presented a largely
renal-limited phenotype, with no neurological involve-
ment. The isolated dysplastic ear without deafness is
probably an unrelated finding. Of interest, the renal
disease in our child manifested earlier when compared
to the other reported cases [5]: at the age of 5, signifi-
cant proteinuria resistant to treatment, progressing
towards nephrotic syndrome and ESRF 4 and 5 years
later, respectively.
Because of the late diagnosis of the genetic defect, we
could introduce CoQ10 supplementation only when
renal function was already compromised, so that no
improvements could have been expected. Conversely, at
least a slower progression toward ESRF could have been
hoped if the treatment was earlier introduced. A signifi-
cant decrease of proteinuria was observed in two
patients who were started on CoQ10 supplementations
while they were still asymptomatic with only a minimal
proteinuria and normal kidney function [4, 9].
Conclusion
Persisting proteinuria even in an asymptomatic child is a
worrying sign, which requires extensive investigations.
The prompt use of the new-generation genetic tools
allowing rapid diagnosis, could avoid the use of poten-
tially toxic treatments. Moreover, if a mutation is found
in one of the genes involved in CoQ10 biosynthesis, sup-
plementation with oral CoQ10 may reverse proteinuria
and stabilize kidney function if started early in the
disease course. ADCK4-related glomerulopathy is an im-
portant novel and potentially treatable cause of isolated
nephropathy not only in adolescents, but also in children
in the first decade of life.
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